Skip to content
DataLookout
Menu

NCT07934927

A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Objective Response Rate (ORR: CR+PR)
Timeframe: up to 18 weeks

Secondary (3)

AEs+SAEs
overall survival(OS)
progress-free survival(RFS)

Arms and interventions

Assigned InterventionsExperimental

Drug: Nab-paclitaxel Injection Nab-paclitaxel 200 mg/m² IV infusion Q3W Drug: Retlirafusp Alfa Injection Retlirafusp Alfa 1 diluted in 250 mL normal saline IV, administered 30 minutes before chemotherapy, Q3W Drug: Apatinib Mesylate Tablet Apatinib Mesylate 250 mg PO QD Regimen: Nab-paclitaxel + Retlirafusp Alfa + Apatinib Mesylate, Q3W × 6 cycles (combination phase); maintenance: Apatinib Mesylate + Retlirafusp Alfa until disease progression or unacceptable toxicity

Drugs: Retlirafusp Alfa Injection

Sites

1 site in 1 country

  • Sun yat-sen uniersityGuangzhou, Guangdong, China